Sei Investments Co. Purchases 18,055 Shares of Genmab A/S Sponsored ADR $GMAB

Sei Investments Co. lifted its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 24.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,012 shares of the company’s stock after purchasing an additional 18,055 shares during the quarter. Sei Investments Co.’s holdings in Genmab A/S were worth $2,496,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Paradigm Biocapital Advisors LP bought a new stake in Genmab A/S during the 3rd quarter valued at $117,063,000. Orbis Allan Gray Ltd lifted its stake in shares of Genmab A/S by 30.2% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after buying an additional 3,340,456 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Genmab A/S by 84.3% during the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Finally, Pictet Asset Management Holding SA acquired a new position in shares of Genmab A/S during the fourth quarter valued at about $33,835,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $31.25 on Friday. The firm has a 50-day moving average of $27.31 and a 200-day moving average of $28.01. The company has a market cap of $19.49 billion, a P/E ratio of 24.61, a P/E/G ratio of 1.96 and a beta of 0.83. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. Genmab A/S Sponsored ADR has a one year low of $21.00 and a one year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 15.02%. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Truist Financial assumed coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. HC Wainwright raised their price target on shares of Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Finally, New Street Research set a $43.00 target price on Genmab A/S in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $39.50.

More Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
• Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
• Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
• Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.